159 related articles for article (PubMed ID: 36120008)
1. Assay Performance of a Label-Free, Solution-Phase CYFRA 21-1 Determination.
Kussrow AK; Kammer MN; Massion PP; Webster R; Bornhop DJ
ACS Omega; 2022 Sep; 7(36):31916-31923. PubMed ID: 36120008
[TBL] [Abstract][Full Text] [Related]
2. Compensated Interferometry Measures of CYFRA 21-1 Improve Diagnosis of Lung Cancer.
Kammer MN; Kussrow AK; Webster RL; Chen H; Hoeksema M; Christenson R; Massion PP; Bornhop DJ
ACS Comb Sci; 2019 Jun; 21(6):465-472. PubMed ID: 31022347
[TBL] [Abstract][Full Text] [Related]
3. Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry.
Olmsted IR; Hassanein M; Kussrow A; Hoeksema M; Li M; Massion PP; Bornhop DJ
Anal Chem; 2014 Aug; 86(15):7566-74. PubMed ID: 24954171
[TBL] [Abstract][Full Text] [Related]
4. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer.
Sánchez-Carbayo M; Espasa A; Chinchilla V; Herrero E; Megías J; Mira A; Soria F
Clin Chem; 1999 Nov; 45(11):1944-53. PubMed ID: 10545064
[TBL] [Abstract][Full Text] [Related]
5. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
6. A novel immunoassay for the quantization of CYFRA 21-1 in human serum.
He A; Liu TC; Dong ZN; Ren ZQ; Hou JY; Li M; Wu YS
J Clin Lab Anal; 2013 Jul; 27(4):277-83. PubMed ID: 23852784
[TBL] [Abstract][Full Text] [Related]
7. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.
Pariente JL; Bordenave L; Jacob F; Gobinet A; Leger F; Ferriere JM; Le Guillou M
J Urol; 2000 Apr; 163(4):1116-9. PubMed ID: 10737478
[TBL] [Abstract][Full Text] [Related]
8. Urine and serum concentrations of Cytokeratin 19 in preeclampsia.
Kuessel L; Wild J; Haslacher H; Perkmann T; Ristl R; Zeisler H; Schmid M
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():311-5. PubMed ID: 25203310
[TBL] [Abstract][Full Text] [Related]
9. Unlabeled lysophosphatidic acid receptor binding in free solution as determined by a compensated interferometric reader.
Ray M; Nagai K; Kihara Y; Kussrow A; Kammer MN; Frantz A; Bornhop DJ; Chun J
J Lipid Res; 2020 Aug; 61(8):1244-1251. PubMed ID: 32513900
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
11. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract][Full Text] [Related]
12. [Basic and clinical studies on serum cytokeratin 19 fragment assay using Centocor CYFRA 21-1 kit in patients with lung cancer].
Hamase A; Sugimoto Y; Maeda M; Kitani H; Fukuchi M
Kaku Igaku; 1994 Aug; 31(8):969-76. PubMed ID: 7523748
[TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay.
Sarwar M; Tomiyoshi K; Inoue T; Fukazawa K; Endo K
Ann Nucl Med; 1994 Nov; 8(4):301-6. PubMed ID: 7535552
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
16. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer.
Wu HH; Wang PH; Yeh JY; Chen YJ; Yen MS; Huang RL; Tsai YJ; Yuan CC
Taiwan J Obstet Gynecol; 2014 Mar; 53(1):30-4. PubMed ID: 24767643
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment.
Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J
Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
20. Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer.
Chapman MH; Sandanayake NS; Andreola F; Dhar DK; Webster GJ; Dooley JS; Pereira SP
J Clin Exp Hepatol; 2011 Jun; 1(1):6-12. PubMed ID: 22228935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
